Survodutide

Survodutide — GLP-1/Glucagon Dual Agonist by Dragon Pharma

Survodutide (BI 456906) is Dragon Pharma's formulation of Boehringer Ingelheim's once-weekly GLP-1/Glucagon dual agonist at 10mg per vial — the Western pharmaceutical counterpart to Mazdutide in the GLP-1+Glucagon category, developed by one of the world's largest pharmaceutical companies with a clinical programme spanning both obesity and liver disease. Survodutide shares the GLP-1/Glucagon dual mechanism with Mazdutide but has distinct clinical data, particularly from its Phase II NASH programme — the most specific liver disease data of any compound in the Dragon Pharma weight management range.

Also searched as: Survodutide, BI 456906, Boehringer Ingelheim GLP-1 glucagon, Survodutide weight loss, Survodutide Dragon Pharma.

What Survodutide Is — Boehringer Ingelheim's GLP-1/Glucagon Agonist

Understanding Survodutide's developer and development context distinguishes it from other compounds in this category:

• Survodutide (internal code BI 456906) was developed by Boehringer Ingelheim — a privately held German pharmaceutical company and one of the world's 20 largest by revenue. This is a significantly different development context from Mazdutide (Innovent Biologics, China) and from the research peptide origins of most other compounds in this range
• Boehringer Ingelheim has a specific strategic focus on metabolic disease and liver conditions — the Survodutide programme reflects this, with parallel clinical development arms for obesity and non-alcoholic steatohepatitis (NASH/MAFLD)
• Survodutide uses a fatty acid conjugation approach for albumin binding — the same mechanism that extends Semaglutide's half-life to ~7 days — producing the once-weekly dosing profile
• Like all GLP-1/Glucagon dual agonists, Survodutide balances the appetite-suppressing, gastric-emptying-slowing effects of GLP-1R activation with the hepatic lipolysis and thermogenic energy expenditure effects of glucagon receptor activation

The NASH Clinical Programme — Survodutide's Specific Liver Data

This is Survodutide's most distinct clinical feature compared to other GLP-1+Glucagon compounds:

• Non-alcoholic steatohepatitis (NASH, now more commonly termed MASH — Metabolic dysfunction-Associated SteatoHepatitis) is a progressive liver disease involving inflammation and fibrosis on top of fatty liver — a condition with no approved treatments until very recently
• Boehringer Ingelheim conducted a dedicated Phase II trial of Survodutide in NASH/MASH patients — reporting results in 2023-2024 that showed significant improvements in liver histology (biopsy-confirmed reduction in inflammation and fibrosis) in a meaningful proportion of patients
• The liver fibrosis resolution rate from Survodutide's NASH Phase II provides a specific and measurable endpoint beyond body weight reduction — making it the compound with the most specific liver disease clinical data in the Dragon Pharma weight management range
• For AAS users specifically: AAS use — particularly oral 17-AA compounds and higher-dose injectable protocols — is associated with liver stress, elevated liver enzymes and in some cases NAFLD (non-alcoholic fatty liver disease). Survodutide's documented liver fibrosis reduction mechanism is directly relevant to this population

Survodutide Clinical Weight Loss Data

Survodutide vs Mazdutide — The GLP-1/Glucagon Comparison

Both are GLP-1/Glucagon dual agonists — the key distinctions are developer, clinical programme focus and regulatory trajectory:

The GLP-1/Glucagon Mechanism — Why It Matters

As with Mazdutide, understanding why Glucagon adds something GLP-1 alone cannot is essential:

• GLP-1 receptor activation: appetite suppression via hypothalamic signalling, gastric emptying delay, insulin secretagogue
• Glucagon receptor activation: direct hepatic lipolysis (triglyceride breakdown in liver), increased thermogenic energy expenditure, fatty acid oxidation upregulation — the mechanisms specifically relevant for liver fat reduction
• The GLP-1 component partially counteracts the hyperglycaemic effect of glucagon at therapeutic doses — producing the net glucose-neutral or mildly glucose-lowering combined effect that makes the combination clinically viable

Effects and Benefits

• ~14.9% body weight reduction over 46 weeks at highest Phase II dose
• Specific liver fibrosis and NASH improvement data — biopsy-confirmed histological benefit in Phase II NASH trial
• Direct hepatic lipolysis from glucagon receptor component — liver fat reduction alongside body weight reduction
• Increased thermogenic energy expenditure from glucagon receptor signalling
• No testosterone suppression — no PCT required
• Once-weekly dosing from the ~1-week half-life

Dosage and Administration

At 10mg per vial, a 2.4mg/week protocol provides approximately 4 doses per vial. Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated at 2-8°C for up to 28 days. Once-weekly injection can be taken at any time — consistency of day matters more than meal timing.